GT Biopharma (GTBP) had the best year between 2011 and 2019 by a US stock in 2012, returning 3,044,698,370%.
| ASSET | YEAR | % RETURN |
|---|---|---|
InnovAge (INNV) | 2011 | 2,566.67% |
Sequans Communications (SQNS) | 2011 | 3,349,297.59% |
BioLineRx (BLRX) | 2011 | 30,621.52% |
Castellum (CTM) | 2011 | 6,521,639.13% |
Nova Lifestyle I (NVFY) | 2011 | 2,733.33% |
GT Biopharma (GTBP) | 2012 | 3,044,698,370% |
QXO (QXO) | 2012 | 1,151,950% |
Intellinetics (INLX) | 2012 | 8,066.67% |
Actinium Pharmaceuticals (ATNM) | 2012 | 1,400% |
Par Pacific (PARR) | 2012 | 1,900% |
Vivakor (VIVK) | 2013 | 1,126.43% |
NextTrip (NTRP) | 2013 | 1,175.86% |
Nutex Health (NUTX) | 2013 | 749,900.2% |
DarioHealth (DRIO) | 2013 | 1,250% |
Almonty Industries Inc Common Shares (ALM) | 2013 | 849.8% |
Andretti Acquisition Corp II Class A Ordinary Shares (POLE) | 2014 | 896.73% |
PCB Bancorp (PCB) | 2014 | 527,363,000% |
Ainos (AIMD) | 2014 | 2,057.89% |
PetVivo (PETV) | 2014 | 64,689.33% |
Inventrust Properties (IVT) | 2014 | 1,067,615% |
GT Biopharma (GTBP) | 2015 | 9,042.86% |
Eastside Distilling (BLNE) | 2015 | 7,995.95% |
SurgePays (SURG) | 2015 | 4,400% |
Cidara Therapeutics (CDTX) | 2015 | 2,045% |
LM Funding America (LMFA) | 2015 | 29,866.29% |
